Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines

References

• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10, 780–786 (2003).
   PubMedGoogle Scholar
• Denis F, Rey JL, Amadou A et al. Emergence of meningococcal meningitis caused by W 135 subgroup in Africa. Lancet2, 1335–1336 (1982).
   PubMedGoogle Scholar
• Fonkoua MC, Taha MK, Nicolas P et al. Recent increase in meningitis caused by Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon. Emerg. Infect. Dis.8, 327–329 (2002).
   PubMed Web of Science ®Google Scholar
• Kwara A, Adegbola RA, Corrah PT et al. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa. Trop. Med. Int. Health3, 742–746 (1998).
   PubMed Web of Science ®Google Scholar
• Guibourdenche M, Hoiby EA, Riou JY et al. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989–94. Epidemiol. Infect.116, 115–120 (1996).
   PubMed Web of Science ®Google Scholar
• WHO. Neisseria meningitidis strains identified in Africa. Weekly Epidemiol. Record68, 311–312 (1993).
   PubMedGoogle Scholar
• Mayer LW, Reeves MW, Al-Hamdan N et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain, but clonal expansion within the electrophoretic type 37 complex. J. Infect. Dis.185, 1596–1605 (2002).
   PubMed Web of Science ®Google Scholar
• Taha MK, Achtman M, Alonso JM et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet356, 2159–2159 (2000).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin. Infect. Dis.36, 679–683 (2003).
   PubMed Web of Science ®Google Scholar
• Issa M, Molling P, Unemo M et al.Neisseria meningitidis serogroup W-135 isolated from healthy carriers and patients in Sudan after the Hajj in 2000. Scand. J. Infect. Dis.35, 230–233 (2003).
   PubMedGoogle Scholar
• Hahne SJ, Gray SJ, Jean F et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet359, 582–583 (2002).
   PubMed Web of Science ®Google Scholar
• Aguilera JF, Perrocheau A, Meffre C, Hahne S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg. Infect. Dis.8, 761–767 (2002).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Barkham TM, Earnest A, Paton NI. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. Br. Med. J.325, 365–366 (2002).
   PubMed Web of Science ®Google Scholar
• Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J. Infect. Dis.167, 1320–1329 (1993).
   PubMed Web of Science ®Google Scholar
• Koumare B, Achtman M, Bougoudogo F, Cisse M, Wang JF. Molecular epidemiology of meningococcal meningitis in Mali: isolation of a new class 1 protein variant (P1.y). Bull. World Health Organ.74, 375–379 (1996).
   PubMedGoogle Scholar
• Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg.93, 341–353 (1999).
   PubMed Web of Science ®Google Scholar
• Riou JY, Djibo S, Sangare L et al. A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull. World Health Organ.74, 181–187 (1996).
   PubMed Web of Science ®Google Scholar
• Lancellotti M, Guiyoule A, Ruckly C et al. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect.8, 191–196 (2006).
   PubMed Web of Science ®Google Scholar
• Stefanelli P, Fazio C, Neri A, Sofia T, Mastrantonio P. First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy. J. Clin. Microbiol.41, 5783–5786 (2003).
   PubMed Web of Science ®Google Scholar
• Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis [letter]. N. Engl. J. Med.342, 219–220 (2000).
   PubMed Web of Science ®Google Scholar
• Swartley JS, Marfin AA, Edupuganti S et al. Capsule switching of Neisseria meningitidis. Proc. Natl Acad. Sci. USA94, 271–276 (1997).
   PubMed Web of Science ®Google Scholar
• Taha MK, Parent DCI, Schlumberger M et al.Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J. Clin. Microbiol.40, 1083–1084 (2002).
   PubMed Web of Science ®Google Scholar
• Ouedraogo-Traore R, Hoiby EA, Sanou I et al. Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand. J. Infect. Dis.34, 804–807 (2002).
   PubMedGoogle Scholar
• Parent du Chatelet I, Traore Y, Gessner BD et al. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. Clin. Infect. Dis.40, 17–25 (2005).
   PubMed Web of Science ®Google Scholar
• Decosas J, Koama JBT. Chronicle of an outbreak foretold: meningococcal meningitidis W135 in Burkina Faso. Lancet763–765 (2002).
   PubMedGoogle Scholar
• WHO. Epidemic meningitis: surveillance and response activities during the 2002–2003 season in the countries of the African meningitis belt. Report on an informal WHO consultation. WHO, Geneva 24–25 2003.
   Google Scholar
• Forgor AA, Leimkugel J, Hodgson A et al. Emergence of W135 meningococcal meningitis in Ghana. Trop. Med. Int. Health10, 1229–1234 (2005).
   PubMedGoogle Scholar
• World Health Organization. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Weekly Epidemiol. Rep.80(37), 313–320 (2005).
   PubMedGoogle Scholar
• WHO. Meningococcal disease, African meningitis belt, epidemic season 2006. Weekly Epidemiol. Rep.81(13), 313–320 (2006).
   Google Scholar
• Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC. Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1. Can. J. Biochem.54, 1–8 (1976).
   PubMedGoogle Scholar
• Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IP. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem.250, 1926–1932 (1975).
   PubMed Web of Science ®Google Scholar
• Claus H, Borrow R, Achtman M et al. Genetics of capsule O-acetylation in serogroup C, W135 and Y meningococci. Mol. Microbiol.51, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Nicolas P, Djibo S, Moussa A et al. Molecular epidemiology of meningococci isolated in Niger in 2003 shows serogroup A sequence type (ST)-7 and serogroup W135 ST-11 or ST-2881 strains. J. Clin. Microbiol.43, 1437–1438 (2005).
   PubMed Web of Science ®Google Scholar
• Moore PS. Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process. Clin. Infect. Dis.14, 515–525 (1992).
   PubMed Web of Science ®Google Scholar
• Crowe BA, Wall RA, Kusecek B et al. Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa. J. Infect. Dis.159, 686–700 (1989).
   PubMed Web of Science ®Google Scholar
• Olyhoek T, Crowe BA, Achtman M. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Rev. Infect. Dis.9, 665–692 (1987).
   PubMedGoogle Scholar
• Njanpop-Lafourcade BM, Parent du Chatelet I, Sanou O, Alonso JM, Taha MK. The establishment of Neisseria meningitidis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the persistence of serogroup A isolates in Burkina Faso. Microbes Infect.7, 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J. Clin. Microbiol.43, 5129–5135 (2005).
   PubMed Web of Science ®Google Scholar
• Taha MK, Alonso JM, Cafferkey M et al. Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J. Clin. Microbiol.43, 144–149 (2005).
   PubMed Web of Science ®Google Scholar
• Guiver M, Borrow R. PCR Diagnosis. In: Meningococcal disease. Methods and Protocols. Pollard AJ, Maiden MCJ (Eds). Humana Press Inc., Totowa, NJ, USA 23–40 (2001).
   Google Scholar
• Orvelid P, Backman A, Olcen P. PCR identification of the group A Neisseria meningitidis gene in cerebrospinal fluid. Scand. J. Infect. Dis.31, 481–483 (1999).
   PubMedGoogle Scholar
• Bennett DE, Mulhall RM, Cafferkey MT. PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z. J. Clin. Microbiol.42, 1764–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Birtles A, Hardy K, Gray SJ et al. Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters. J. Clin. Microbiol.43, 6007–6014 (2005).
   PubMedGoogle Scholar
• Djibo S, Njanpop-Lafourcade BM, Boisier P et al. Evaluation of the Pastorex® meningitis kit for the rapid identification of Neisseria meningitidis serogroups A and W135. Trans. R. Soc. Trop. Med. Hyg.100, 573–578 (2006).
   Google Scholar
• Sidikou F, Djibo S, Taha MK et al. Polymerase chain reaction assay and bacterial meningitis surveillance in remote areas, Niger. Emerg. Infect. Dis.9, 1486–1488 (2003).
   PubMed Web of Science ®Google Scholar
• Vienne P, Ducos-Galand M, Guiyoule A et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin. Infect. Dis.37, 1639–1642 (2003).
   PubMed Web of Science ®Google Scholar
• Faye A, Mariani-Kurkdjian P, Taha MK et al. Clinical features and outcome of pediatric Neisseria meningitidis serogroup W135 infection: a report of 5 cases. Clin. Infect. Dis.38, 1635–1637 (2004).
   PubMed Web of Science ®Google Scholar
• Molyneux EM, Walsh AL, Forsyth H et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet360, 211–218 (2002).
   PubMed Web of Science ®Google Scholar
• Mwangi I, Berkley J, Lowe B et al. Acute bacterial meningitis in children admitted to a rural Kenyan hospital: increasing antibiotic resistance and outcome. Pediatr. Infect. Dis. J.21, 1042–1048 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis RF, Dorlencourt F, Pinel J. Long-acting oily chloramphenicol for meningococcal meningitis. Lancet352, 823 (1998).
   PubMed Web of Science ®Google Scholar
• Nathan N, Borel T, Djibo A et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet366, 308–313 (2005).
   PubMed Web of Science ®Google Scholar
• Duke T, Michael A, Mokela D, Wal T, Reeder J. Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries? Arch. Dis. Child.88, 536–539 (2003).
   PubMed Web of Science ®Google Scholar
• Pinner RW, Onyango F, Perkins BA et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group. J. Infect. Dis.166, 359–364 (1992).
   PubMed Web of Science ®Google Scholar
• Boisier P, Djibo S, Sidikou F et al. Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135. Trop. Med. Int. Health10, 435–443 (2005).
   PubMedGoogle Scholar
• Bertherat E, Yada A, Djingarey MH, Koumare B. First major epidemic caused by Neisseria meningitidis serogroup W135 in Africa? Med. Trop. (Mars)62, 301–304 (2002).
   PubMedGoogle Scholar
• Koumare B, Bougoudogo F, Cisse M, Doumbia T, Keita MM. Bacteriological aspects of purulent meningitis in Bamako district. Apropos of 1,541 bacterial strains collected from 1979 to 1991. Bull. Soc. Pathol. Exot.86, 136–140 (1993).
   PubMedGoogle Scholar
• Greenwood BM, Blakebrough IS, Bradley AK, Wali S, Whittle HC. Meningococcal disease and season in sub-Saharan Africa. Lancet1, 1339–1342 (1984).
   PubMed Web of Science ®Google Scholar
• Mueller JE, Yaro S, Traore Y et al.Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003. J. Infect. Dis.193, 812–820 (2006).
   PubMedGoogle Scholar
• Blakebrough IS, Greenwood BM, Whittle HC, Bradley AK, Gilles HM. The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. J. Infect. Dis.146, 626–637 (1982).
   PubMed Web of Science ®Google Scholar
• Molesworth AM, Cuevas LE, Connor SJ, Morse AP, Thomson MC. Environmental risk and meningitis epidemics in Africa. Emerg. Infect. Dis.9, 1287–1293 (2003).
   PubMed Web of Science ®Google Scholar
• Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux JP. Epidemiology of bacterial meningitis in Niamey, Niger, 1981–1996. Bull. WHO499–508 (1997).
   Google Scholar
• Musher DM. How contagious are common respiratory tract infections? N. Engl. J. Med.348, 1256–1266 (2003).
   PubMed Web of Science ®Google Scholar
• McCall BJ, Neill AS, Young MM. Risk factors for invasive meningococcal disease in southern Queensland, 2000–2001. Intern. Med. J.34, 464–468 (2004).
   PubMed Web of Science ®Google Scholar
• Pereiro I, Diez-Domingo J, Segarra L et al. Risk factors for invasive disease among children in Spain. J. Infect.48, 320–329 (2004).
   PubMed Web of Science ®Google Scholar
• Baker M, McNicholas A, Garrett N et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr. Infect. Dis. J.19, 983–990 (2000).
   PubMed Web of Science ®Google Scholar
• Stanwell-Smith RE, Stuart JM, Hughes AO et al. Smoking, the environment and meningococcal disease: a case control study. Epidemiol. Infect.112, 315–328 (1994).
   PubMed Web of Science ®Google Scholar
• Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Stat. Quart.50, 170–177 (1997).
   PubMedGoogle Scholar
• Hastings L, Stuart J, Andrews N, Begg N. A retrospective survey of clusters of meningococcal disease in England and Wales, 1993 to 1995: estimated risks of further cases in household and educational settings. Commun. Dis. Rep. CDR Rev.7, R195–R200 (1997).
   PubMedGoogle Scholar
• Hodgson A, Smith T, Gagneux S et al. Risk factors for meningococcal meningitis in northern Ghana. Trans. R. Soc. Trop. Med. Hyg.95, 477–480 (2001).
   PubMedGoogle Scholar
• Moore PS, Hierholzer J, DeWitt W et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis [see comments]. JAMA264, 1271–1275 (1990).
   PubMed Web of Science ®Google Scholar
• Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA260, 2686–2689 (1988).
   PubMed Web of Science ®Google Scholar
• Greenwood BM, Greenwood AM, Bradley AK et al. Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa. J. Infect.14, 167–184 (1987).
   PubMed Web of Science ®Google Scholar
• Whittle HC, Werblinska J, Hassan-King M et al. Is there a genetic immune defect in families with meningococcal meningitis? J. Infect.3, 140–149 (1981).
   PubMed Web of Science ®Google Scholar
• Allen A, Obaro S, Bojang K et al. Variation in toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr. Infect. Dis. J.22, 1018–1019 (2003).
   PubMed Web of Science ®Google Scholar
• Raghunathan PL, Jones JD, Tiendrebeogo SR et al. Predictors of Immunity after a Major Serogroup W-135 Meningococcal Disease Epidemic, Burkina Faso, 2002. J. Infect. Dis.193, 607–616 (2006).
   PubMedGoogle Scholar
• Amadou Hamidou A DS, Moussa A et al. Asymptomatic carriage of serogroup W135 meningococcus in Niamey (Niger): relationship with acquired protective immunity. Presented at Medicine and Health in the Tropics. Marseille, France, 11–15 September, Abstract YI–Y163. In, 2005.
   Google Scholar
• Boisier PNP, Djibo S, Amadou–Hamidou A, Sidikou F, Chanteau S. Self-contained outburst of meningitis due to Neisseria meningitidis serogroup W135, ST-2881, in Niger with high reate of asymptomatic carriage in the community. Presented at Medicine and Health in the Tropics. Marseille, France, 11–15 September, Abstract P591 (2005).
   Google Scholar
• Saliou P, Thabaut A, Durosoir JL. Sensitivity study for sulfamides and antibiotics of 260 strains of Neisseria meningitidis isolated in Upper Volta. Bull. Soc. Pathol. Exot. Filiale.74, 263–272 (1981).
   PubMedGoogle Scholar
• Gagneux SP, Hodgson A, Smith TA et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J. Infect. Dis.185, 618–626 (2002).
   PubMed Web of Science ®Google Scholar
• Odugbemi T, Ademidun O, Agbabiaka A, Banjo T. Nasopharyngeal carriage of Neisseria meningitidis among school children at Ijede, Lagos State, Nigeria. Ethiop. Med. J.30, 33–36 (1992).
   PubMedGoogle Scholar
• MacLennan JM, Urwin R, Obaro S et al. Carriage of serogroup W-135, ET-37 meningococci in The Gambia: implications for immunisation policy? Lancet356, 1078 (2000).
   PubMedGoogle Scholar
• Djibo S, Nicolas P, Campagne G, Chippaux JP. Pharyngeal carriage of Neisseria meningitidis in a school of Niamey, Niger. Med. Trop. (Mars)64, 363–366 (2004).
   PubMedGoogle Scholar
• Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J. Infect.16, 55–59 (1988).
   PubMed Web of Science ®Google Scholar
• Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis.9, 105–110 (1977).
   PubMed Web of Science ®Google Scholar
• Boutet R, Stuart JM, Kaczmarski EB et al. Risk of laboratory-acquired meningococcal disease. J. Hosp. Infect.49, 282–284 (2001).
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol.53, 821–832 (2004).
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R. Serolgic correlates of protection for evaluating the response to meningococcal vaccine. Expert Rev. Vaccines3(1), 77–87 (2004).
   PubMedGoogle Scholar
• Fernandez J, Levine OS, Sanchez J et al. Prevention of Haemophilus influenzae type B colonization by vaccination: correlation with serum anti-capsular IgG concentration. J. Infect. Dis.182, 1553–1556 (2000).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Hussain M, Andrews N et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J. Infect. Dis.192, 387–393 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Mazrou Y, Khalil M, Borrow R et al. Immunogenicity of a meningococcal ACYW135 polysaccharide vaccine in Saudi children aged under 2 years. Infect. Immun.73, 2932–2939 (2005).
   PubMed Web of Science ®Google Scholar
• Khalil M, Al-Mazrou Y, Balmer P et al. Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age. Clin. Diagn. Lab. Immunol.12, 1251–1253 (2005).
   PubMedGoogle Scholar
• Antignac A, Ducos-Garland M, Guiyoule A, Pries R, Alonso JM, Taha MK. Neisseria meningitidis strains isolated from invasive infection in France (1999–2002): phenotypes and antibiotic susceptibility patterns. Clin. Infect. Dis.37(7), 912–920 (2003).
   PubMed Web of Science ®Google Scholar
• Dull PM, Abdelwahab J, Sacchi CT et al.Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. J. Infect. Dis.191, 33–39 (2005).
   PubMedGoogle Scholar
• Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359, 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Kriz P, Kriz B, Svandova E, Musilek M. Antimeningococcal herd immunity in the Czech Republic – influence of an emerging clone, Neisseria meningitidis ET-15/37. Epidemiol. Infect.123, 193–200 (1999).
   PubMed Web of Science ®Google Scholar
• Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis.191, 1263–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine23, 977–983 (2005).
   PubMedGoogle Scholar
• Vodopija I, Baklaic Z, Hauser P et al. Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide. Infect. Immun.42, 599–604 (1983).
   PubMed Web of Science ®Google Scholar
• Cadoz M, Armand J, Arminjon F, Gire R, Lafaix C. Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: immunogenicity and safety. Vaccine3, 340–342 (1985).
   Google Scholar
• Ambrosch F, Wiedermann G, Crooy P, George AM. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull. World Health Organ.61, 317–323 (1983).
   PubMed Web of Science ®Google Scholar
• Campbell JD, Edelman R, King JC Jr. et al. Safety, reactogenicity and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J. Infect. Dis.186, 1848–1851 (2002).
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Blatter M et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr. Infect. Dis. J.24, 57–62 (2005).
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med.159, 907–913 (2005).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Morgan A, Welsch JA. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children. Vaccine23, 4307–4314 (2005).
   PubMedGoogle Scholar
• Fijen CA, Kuijper EJ, Drogari-Apiranthitou M et al. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin. Exp. Immunol.114, 362–369 (1998).
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med.129, 1327–1348 (1969).
   PubMed Web of Science ®Google Scholar
• Reller LB, MacGregor RR, Beaty HN. Bactericidal antibody after colonization with Neisseria meningitidis. J. Infect. Dis.127, 56–62 (1973).
   PubMedGoogle Scholar
• Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol.51, 717–722 (2002).
   PubMed Web of Science ®Google Scholar
• Diggle MA, Clarke SC. Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J. Clin. Microbiol.43, 4649–4653 (2005).
   PubMed Web of Science ®Google Scholar
• Taha MK DA, Antignac A, Zarantonelli ML, Larribe M, Alonso A. The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol.10, 376–382 (2002).
   PubMed Web of Science ®Google Scholar
• Bille E, Zahar JR, Perrin A et al. A chromosomally integrated bacteriophage in invasive meningococci. J. Exp. Med.201, 1905–1913 (2005).
   PubMed Web of Science ®Google Scholar
• Artenstein MS, Gold R, Zimmerly JG et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med.282, 417–420 (1970).
   PubMed Web of Science ®Google Scholar
• Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–70. Bull. World Health Organ.45, 279–282 (1971).
   PubMed Web of Science ®Google Scholar
• Wahdan MH, Rizk F, el Akkad AM et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. World Health Organ.48, 667–673 (1973).
   PubMed Web of Science ®Google Scholar
• Erwa HH, Haseeb MA, Idris AA et al. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull. World Health Organ.49, 301–305 (1973).
   PubMed Web of Science ®Google Scholar
• WHO. Requirements for meningococcal polysaccharide vaccine. WHO Tech. Rep. Ser.594, 50–75 (1976).
   Google Scholar
• Nicolas P. Menomune: a tetravalent vaccine for the prophylaxis of meningococcal infections of types A, C, W135, Y. Med. Trop. (Mars)62, 129–131 (2002).
   PubMedGoogle Scholar
• Anonymous. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol. Rec.77, 331–339 (2002).
   Google Scholar
• Balkhy HH, Memish ZA, Almuneef MA, Osoba AO. Neisseria meningitidis W-135 carriage during the Hajj season 2003. Scand. J. Infect. Dis.36, 264–268 (2004).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarro M, Toe L, Tiendrebeogo S et al. Effectiveness of a serogroup A/C/W-135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Presented at the 14th International Pathogenic Neisseria Conference,. Milwaukee, USA, September 5–10, Abstract book 5, (2004).
   Google Scholar
• Peltola H, Safary A, Kayhty H, Karanko V, Andre FE. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics76, 91–96 (1985).
   Google Scholar
• Rennels M, King J Jr, Ryall R et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr. Infect. Dis. J.21, 978–979 (2002).
   PubMed Web of Science ®Google Scholar
• Rennels M, King J, Jr., Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.23, 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• El Bashir H, Heath PT, Papa T et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine24, 2544–2549 (2006).
   Google Scholar
• Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis.154, 1033–1036 (1986).
   PubMed Web of Science ®Google Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J. Infect. Dis.193, 821–828 (2006).
   PubMed Web of Science ®Google Scholar
• Ismail AA, Harris SL, Granoff DM. Serum group A anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr. Infect. Dis. J.23, 748–755 (2004).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R, Gotschlich EC et al. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull. World Health Organ.81, 745–750 (2003).
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340, 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14, 195–207 (1991).
   PubMedGoogle Scholar
• Cruz C, Pavez G, Aguilar E et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol. Infect.105, 119–126 (1990).
   PubMed Web of Science ®Google Scholar
• Holst J, Aaberge IS, Oster P et al. A ‘tailor made’ vaccine trialled as part of public health response to group B meningococal epidemic in New Zealand. Eurosurveillance Weekly7, 6–9 (2003).
   Google Scholar
• Norheim G, Aase A, Caugant DA et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine23, 3762–3274 (2005).
   PubMedGoogle Scholar
• Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197, 789–799 (2003).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med.195, 1445–1454 (2002).
   PubMed Web of Science ®Google Scholar
• Pillai S, Howell A, Alexander K et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine23, 2206–2209 (2005).
   PubMed Web of Science ®Google Scholar
• Hankins WA, Gwaltney JJM, Hendley JO, Farquar JD, Samuelson JS. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y and W135(41306). Proc. Soc. Expert Biol. Med.169, 54–57 (1982).
   PubMedGoogle Scholar
• Griffiss JM, Brandt BL, Altieri PL, Pier GB, Berman SL. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect. Immun.34, 725–732 (1981).
   PubMed Web of Science ®Google Scholar
• Platonov AE, Beloborodov VB, Pavlova LI, Vershinina IV, Kayhty H. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine. Clin. Exp. Immunol.100, 32–39 (1995).
   PubMedGoogle Scholar